Arcus Biosciences

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arcus Biosciences reports strong Q3 performance with promising trial results

Arcus Biosciences delivered strong financial performance and promising clinical trial results in Q3 2023.
The company faces financial challenges amidst high R&D expenses but maintains a solid cash position and operational strength.
Strategic opportunities exist in advancing differentiated therapies, navigating competitive landscapes, and exploring combination treatments.
Successfully addressing challenges and capitalizing on opportunities can drive growth and market success for Arcus Biosciences.

Arcus Biosciences excels in Q4, poised for oncology innovation

Arcus Biosciences reported strong financials, positive program results, and strategic partnerships, positioning the company for continued growth and innovation in oncology.
Operational changes reflect a proactive approach to portfolio optimization and trial advancement, demonstrating Arcus's commitment to maximizing program potential and patient impact.
Challenges in data interpretation, program comparisons, and trial planning require careful navigation, while upcoming opportunities in 2024 offer avenues for showcasing progress and driving future success.
With a focus on expanding patient cohorts, optimizing doses, and revealing trial designs, Arcus is poised to capitalize on opportunities, address challenges, and deliver value to stakeholders.

Arcus Biosciences reports robust Q1 results and advances promising pipeline

Arcus Biosciences showcased strong financials, positive study data, and strategic partnerships, positioning them well for future growth and innovation.
While facing challenges in managing expenses and differentiation strategies, the company is actively exploring opportunities in combination therapies and tumor targeting.
The emphasis on good data, strategic planning, and leveraging biological insights highlights Arcus Biosciences' commitment to advancing drug development efforts and improving patient outcomes.

Arcus Biosciences reports promising clinical results and solid financials

Arcus Biosciences demonstrated strong clinical progress with casdatifan and domvanalimab, supported by solid financial performance. While challenges in clinical trial execution and market competition exist, the company is well-positioned to capitalize on opportunities for growth through upcoming Phase 3 studies and data presentations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcus Biosciences, Inc. (NYSE:RCUS ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Pia Eaves - Head of Investor Relations And Strategy Terry Rosen - Co-Founder, Chairman & CEO Dimitry Nuyten - Chief Medical Officer Jennifer Jarrett - COO & Director Robert Goeltz - Principal Financial & Accounting Officer & CFO Juan Jaen - President and Head of Research Conference Call Participants Yigal Nochomovitz - Citigroup Jonathan Miller - Evercore ISI Peter Lawson - Barclays Bank Robin Karnauskas - Truist Kaveri Pohlman - BTIG Mara Goldstein - Mizuho Securities Rosemary Li - Cantor Fitzgerald & Co. Jason Zemanski - Bank of America Operator Thank you and welcome to the call. Following prepared remarks from the Company, we will open the call for questions.

Arcus Biosciences, Inc. (RCUS) Q3 2023 Earnings Call Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple common cancers. “A.

Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update

Gilead Sciences

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month progression-free survival (PFS) rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study. This ongoing Phase 2, multi-arm, global study is evaluating the safety and efficacy of various combinations of the Fc-silent.

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month progression-free survival (PFS) rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study. This ongoing Phase 2, multi-arm, global study is evaluating the safety and efficacy of various combinations of the Fc-silent.

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers

Arcus Biosciences, Inc. (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society of Clinical Oncology (ASCO) Monthly Plenary Series on November 7, 2023. EDGE-Gastric (also known as ARC-21), a collaboration between Arcus and Gilead Sciences, is a Phase 2 platform study evaluating various combinations of domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, and zimberelimab, an a.

Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7

Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. The company has major deals with Gilead, Roche/Genentech, and AstraZeneca, and a large cash reserve. Gilead continues to increase its stake in Arcus, showing confidence in the company's potential.

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Roche Holding AG

iTeos Therapeutics, Inc.

Roche accidentally published positive interim results from a lung cancer treatment study, which boosted shares of rivals Iteos and Arcus.

How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September: 2023 Wells Fargo Healthcare Conference Date: Wednesday, September 6th, 2023 at 10:15 a.m. ET Location: Boston, MA Format: Fireside Chat Citi 18th Annual BioPharma Conference.

Arcus Biosciences to Participate in Multiple Upcoming Investor Conferences

Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. GILD, +0.54%, Arcus Biosciences Inc. RCUS, -0.84% and iTeos Therapeutics Inc. ITOS, +2.80%, got a boost premarket on Wednesday after Roche AG RHHBY, -1.10% said there had been an “inadvertent disclosure” of interim data from a study of its anti-TIGIT therapy tiragolumab in non-small cell lung cancer. The interim results showed positive data for overall survival with tiragolumab, but the results were “not mature” at the time of the analysis that was disclosed, Roche said in a release.

Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.93 per share a year ago.

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple common cancers. “Beyon.

Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update

Allovir, Inc.

In recent Securities & Exchange Commission filings, Gilead Sciences Inc. NASDAQ: GILD revealed that it had purchased significant stakes in AlloVir Inc. NASDAQ: ALVR and Arcus Biosciences Inc. NYSE: RCUS.

Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. ARC-7 is the first Phase 2, randomized, open-label study evaluating the c.

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, California. The fireside chat will take place on Tuesday, June 13th, 2023.

Arcus Biosciences to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Shares of Arcus Biosciences surged Friday after Roche provided "meaningful" evidence for a new cancer treatment class. The post Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class appeared first on Investor's Business Daily.

Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced seven accepted abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 2-6, 2023. The selected abstracts presented in partnership with Gilead Sciences highlight the company's expanding portfolio of investigational.

Presentations at the 2023 ASCO Annual Meeting Highlight Arcus Biosciences' Expanding Portfolio of Investigational Medicines and Late-Stage Studies Across Multiple Types of Cancer

Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.

Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases

FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases. The expanded collaboration builds upon Gilead's growing presence in inflammatory disease and serves as a step towards broadening Arcus' capabilities and portfolio beyond oncology and i.

Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple common cancers. “Toget.

Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q1 Earnings Expected to Decline

Arcus's pipeline includes several promising candidates, including domvanalimab, an Fc-silent anti-TIGIT antibody, and zimberelimab, an anti-PD-1 antibody. Arcus recently announced positive results from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study.

Arcus Biosciences: Anti-TIGIT Therapy On Track With ARC-7 Results

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Barclays Global Healthcare Conference in Miami Beach, Florida. The fireside chat will take place on Tuesday, March 14th, 2023 at 8:30 a.m. ET.

Arcus Biosciences to Participate in the Barclays Global Healthcare Conference

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 6.06% and 45.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

News for Arcus Biosciences Stock (RCUS)